Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02648711 · ClinicalTrials.gov registry record · Phase 1
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
A Phase 1 study, sponsored by NewLink Genetics Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT02648711 is a Phase 1 study that was terminated before completion, run by NewLink Genetics Corporation. The registered enrollment target is 41 participants.
The verdict
NCT02648711, a Phase 1 study, was terminated before completion, sponsored by NewLink Genetics Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of weekly dosing of CRLX101 (both as monotherapy; (Schedule 1) and in combination with bevacizumab every 2 weeks (Schedule 2) and weekly with a 3 week on / 1 week off schedule in combination with mFOLFOX6 (Schedule 3) to affirm the dose for future clinical studies.
Interventions
- DRUG Bevacizumab
- DRUG mFOLFOX6
- DRUG CRLX101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02648711
The ClinicalTrials.gov registry entry for NCT02648711 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewLink Genetics Corporation, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT02648711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02648711 about?
NCT02648711 is a clinical study titled "Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors". The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of weekly dosing of CRLX101 (both as monotherapy; (Schedule 1) and in combination with bevacizumab every 2 weeks (Schedule 2) and weekly with a 3 week on / 1 week off schedule in combina...
What is the current status of trial NCT02648711?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2015-10. Estimated completion is 2018-05-07.
What interventions are being tested in trial NCT02648711?
The interventions under investigation include: Bevacizumab (DRUG), mFOLFOX6 (DRUG), CRLX101 (DRUG).
Who is sponsoring clinical trial NCT02648711?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.